SCHEMBL1491501

SCHEMBL1491501

Nc1ccc(S(=O)(=O)NC(C(=O)OC2CCCC2)c2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 3/20 0.44
MMP9 P14780 3/20 0.44
ANPEP P15144 2/20 0.44
LTA4H P09960 1/20 0.44
LAP3 P28838 1/20 0.44
NPEPPS P55786 1/20 0.44
ERAP2 Q6P179 1/20 0.44
ERAP1 Q9NZ08 1/20 0.44
ALDH1A1 P00352 4/20 0.42
TSHR P16473 2/20 0.42
SLC1A3 P43003 1/20 0.42
SLC1A2 P43004 1/20 0.42
SLC1A1 P43005 1/20 0.42
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
LMNA P02545 2/20 0.41
MMP1 P03956 1/20 0.40
MMP3 P08254 1/20 0.40
MMP7 P09237 1/20 0.40
MMP13 P45452 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1491497 1.00 MMP2 (0.44) MMP2MMP9ANPEPLTA4HLAP3
SCHEMBL1491512 0.85 KMT2A (0.47) MMP2MMP9ANPEPLTA4HLAP3
SCHEMBL1491514 0.85 KMT2A (0.47) MMP2MMP9ANPEPLTA4HLAP3
SCHEMBL1491328 0.78 HDAC1 (0.46) MMP2MMP9ANPEPLTA4HLAP3
SCHEMBL1491326 0.78 HDAC1 (0.46) MMP2MMP9ANPEPLTA4HLAP3
SCHEMBL1410165 0.77 HDAC8 (0.41) MMP2MMP9ANPEPLTA4HLAP3
SCHEMBL1410163 0.77 HDAC8 (0.41) MMP2MMP9ANPEPLTA4HLAP3
SCHEMBL1411235 0.75 MMP2 (0.40) MMP2MMP9ANPEPLTA4HLAP3
SCHEMBL1411237 0.75 MMP2 (0.40) MMP2MMP9ANPEPLTA4HLAP3
SCHEMBL8201379 0.75 HDAC1 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9133104-B2 Enzyme inhibitors CHROMA THERAPEUTICS LTD. (GB) 2015-09-15 US disclosed
US-20140163042-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2014-06-12 US disclosed
US-20130116318-A1 Enzyme Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2013-05-09 US disclosed
EP-1879895-B1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2011-06-08 EP disclosed
US-7939666-B2 Enzyme inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-05-10 US disclosed
EP-2301939-A1 Enzyme inhibitors Chroma Therapeutics Limited (GB) 2011-03-30 EP disclosed
US-20090291978-A1 Enzyme Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2009-11-26 US disclosed
EP-1879895-A1 ENZYME INHIBITORS Chroma Therapeutics Limited (GB) 2008-01-23 EP disclosed
WO-2006117549-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116318-A1 Enzyme Inhibitors HDAC1, HDAC11, HDAC7 MMP2 59/4885MMP9 77/4885ANPEP 1051/4885
US-20140163042-A1 ENZYME INHIBITORS HAT1, NR2E1, HDAC3 MMP2 183/4885MMP9 486/4885ANPEP 267/4885
US-20090291978-A1 Enzyme Inhibitors HAT1, NR2E1, NR2C2 MMP2 483/4885MMP9 786/4885ANPEP 640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.